Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Podzamczer

Showing results (91-100 of 107) with videos related to

Pageof 11
Sort By:
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|July 1, 1996
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study GroupJ M Gatell, J González-Lahoz, B Clotet, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|January 15, 2014
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, A Gonzalez-Cordon, E Ferrer, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 4, 2000
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study GroupD Podzamczer, J M Miró, E Ferrer, et al.
AIDS (London, England)|December 22, 1999
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 studyF García, J Romeu, I Grau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2008
Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicinL Martín-Carbonero, R Palacios, E Valencia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 13, 2012
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS CohortC Manzardo, A Esteve, N Ortega, et al.
The Journal of Infection|June 24, 2008
HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro, M M Nogueras, F Segura, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2005
Once-daily antiretroviral therapy: Spanish Consensus StatementF Pulido, E Ribera, S Moreno, et al.
Current HIV Research|February 15, 2019
Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR StudyD Podzamczer, N Rozas, P Domingo, et al.
Pageof 11

Showing results (91-100 of 107) with videos related to

Sort By:
Pageof 11
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|July 1, 1996
Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study GroupJ M Gatell, J González-Lahoz, B Clotet, et al.
HIV Clinical Trials|April 19, 2012
Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissueS M E Vrouenraets, F W N M Wit, E Fernandez Garcia, et al.
HIV Medicine|January 15, 2014
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavirE Martinez, A Gonzalez-Cordon, E Ferrer, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|April 4, 2000
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study GroupD Podzamczer, J M Miró, E Ferrer, et al.
AIDS (London, England)|December 22, 1999
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 studyF García, J Romeu, I Grau, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 28, 2008
Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicinL Martín-Carbonero, R Palacios, E Valencia, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 13, 2012
Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS CohortC Manzardo, A Esteve, N Ortega, et al.
The Journal of Infection|June 24, 2008
HIV-1 infected patients older than 50 years. PISCIS cohort studyG Navarro, M M Nogueras, F Segura, et al.
The Journal of Antimicrobial Chemotherapy|September 10, 2005
Once-daily antiretroviral therapy: Spanish Consensus StatementF Pulido, E Ribera, S Moreno, et al.
Current HIV Research|February 15, 2019
Real World Patient-reported Outcomes in HIV-infected Adults Switching to EVIPLERA®, Because of a Previous Intolerance to cART. PRO-STR StudyD Podzamczer, N Rozas, P Domingo, et al.
Pageof 11